Session » (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1151

A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1172

A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease

10:30AM-12:30PM: Abstract Number: 1170

A20 Haploinsufficiency (HA20): TNFAIP3 Mutation Prevalence In A Clinically Compatible Cohort

10:30AM-12:30PM: Abstract Number: 1178

An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)

10:30AM-12:30PM: Abstract Number: 1162

Antineutrophil cytoplasmic antibody-associated isolated interstitial lung disease

10:30AM-12:30PM: Abstract Number: 1188

Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation

10:30AM-12:30PM: Abstract Number: 1154

Assessment Of Damage Using The IgG4-Related Disease Damage Index.

10:30AM-12:30PM: Abstract Number: 1166

Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis

10:30AM-12:30PM: Abstract Number: 1182

Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study

10:30AM-12:30PM: Abstract Number: 1163

Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial

10:30AM-12:30PM: Abstract Number: 1158

Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China

10:30AM-12:30PM: Abstract Number: 1167

Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study

10:30AM-12:30PM: Abstract Number: 1189

Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1181

Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines

10:30AM-12:30PM: Abstract Number: 1161

Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases

10:30AM-12:30PM: Abstract Number: 1152

Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience

10:30AM-12:30PM: Abstract Number: 1184

Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.

10:30AM-12:30PM: Abstract Number: 1164

Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients

10:30AM-12:30PM: Abstract Number: 1179

Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome

10:30AM-12:30PM: Abstract Number: 1180

Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country

10:30AM-12:30PM: Abstract Number: 1174

High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study

10:30AM-12:30PM: Abstract Number: 1190

IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort

10:30AM-12:30PM: Abstract Number: 1159

IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study

10:30AM-12:30PM: Abstract Number: 1150

Impact of IL-17A on synovial fibroblast from subacromial bursae

10:30AM-12:30PM: Abstract Number: 1156

Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort

10:30AM-12:30PM: Abstract Number: 1186

Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry

10:30AM-12:30PM: Abstract Number: 1148

Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center

10:30AM-12:30PM: Abstract Number: 1168

Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory

10:30AM-12:30PM: Abstract Number: 1187

Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 1153

New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida

10:30AM-12:30PM: Abstract Number: 1149

Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study

10:30AM-12:30PM: Abstract Number: 1169

Periodontitis in neutropenic DADA2 patients

10:30AM-12:30PM: Abstract Number: 1160

Plasma Adenosine Deaminase 2 as a Potential Disease Activity Biomarker for Sarcoidosis

10:30AM-12:30PM: Abstract Number: 1177

Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study

10:30AM-12:30PM: Abstract Number: 1173

Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging

10:30AM-12:30PM: Abstract Number: 1185

Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15

10:30AM-12:30PM: Abstract Number: 1165

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors

10:30AM-12:30PM: Abstract Number: 1147

Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes

10:30AM-12:30PM: Abstract Number: 1183

Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors

10:30AM-12:30PM: Abstract Number: 1157

Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months

10:30AM-12:30PM: Abstract Number: 1175

Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study

10:30AM-12:30PM: Abstract Number: 1171

VEXAS Syndrome Under the Lens: A prospective analysis of temporal disease patterns, biomarker Dynamics, and therapeutic efficacy

10:30AM-12:30PM: Abstract Number: 1176

VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation

10:30AM-12:30PM: Abstract Number: 1155

Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].